PK-driven prophylaxis versus standard prophylaxis: When a tailored treatment may be a real and achievable cost-saving approach in children with severe hemophilia A. Issue 157 (September 2017)

• Record Type: Journal Article
• Authors: Pasca, Samantha; Milan, Marta; Sarolo, Lucia; Zanon, Ezio
• Is Part Of: Thrombosis research. Issue 157(2017)
• Page Start: 58
• Page End: 63
• Publication Date: 2017-09
• Subjects: Hemophilia treatment -- Replacement therapy -- Cost of treatment -- Quality of life; Thrombosis -- Periodicals; 616.135
• DOI: 10.1016/j.thromres.2017.07.003
• Languages: English
• ISSNs: 0049-3848

Abstract

Abstract: Background: Prophylaxis is the gold standard for the treatment of children with severe hemophilia. In the last years a new approach to prophylaxis based on annual bleeding rate (ABR), pharmacokinetics (PK) and lifestyle of each patient has begun to be adopted in hemophilia treatment. Aim: Aim of our observational retrospective study was to evaluate whether in a group of children with severe hemophilia A (HA) a tailored approach may be used to replace standard therapy, reducing costs. Methods: PK evaluation was carried out in six hemophiliac children followed at our Hemophilia Center, and already receiving recombinant factor VIII (rFVIII) on prophylaxis, using a computing program ( MyPKfit® ). Bayesian curve was created for each child and tailored prophylaxis was estimated considering a trough level of 1%. Results: The weekly frequency of infusions was reduced in one patient, while it was slightly increased in three children. As to the remaining children, only the dosage was changed. Scheduled follow-up revealed a complete adherence to treatment, a reduction of bleeds using PK-regimen and a general improvement in the quality of life. The comparison between the direct and indirect costs of treatment during standard and PK-driven prophylaxis showed a total saving of € 54, 797.40 (− 10.67%) in case of tailored prophylaxis. Conclusion: A therapeutic approach based on PK and clinical characteristics of each patient may change standard treatment. Based on our results, tailored prophylaxis could be an effective option for children with HA reducing costs. Highlights: PK-driven prophylaxis can reduce costs of the expensive hemophilia treatment. Available resources can be increased, reducing costs of replacement therapy. Tailored prophylaxis is unique and created following the needs and characteristics of each patient. An optimal treatment improves quality of life of children with hemophilia.